1. >
  2. search-en


Found 422 Results
Page 1 of 43

Onxeo will publish its full-year results on April 14, 2023

The annual general meeting will be held on June 6, 2023 Paris (France), March 14, 2023 – 6:00 pm CET […]


Onxeo: report on the Extraordinary General Meeting of February 6, 2023

Paris (France), February 6, 2023 – 7:30 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), […]


Onxeo Announces its Financial Agenda for 2023

Paris (France), January 27, 2023 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), […]


ONXEO provides update on the Development Program for its first-in-class drug candidate AsiDNATM

Phase 1b/2 trial of AsiDNATM in combination with olaparib initiated in the United States in recurrent ovarian, breast and metastatic […]


General Meetings 2023

GENERAL MEETING 2023 Extraordinary General Meeting of 6 February 2023 12/28/2022 – Notice of meeting valid as a convocation published […]


Onxeo advances its second lead candidate OX425 for the treatment of solid tumors

OX425 is a novel DDR Decoy Agonist which also mediates multiple immunostimulatory effects, making it a promising candidate for combination […]


Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities

Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally Cash position of €26.9 million as of June […]


High-Grade Glioma Relapse in Children: Onxeo announces the enrollment of the first patient in the phase 1b/2 clinical study conducted by the European ITCC consortium and sponsored by Institut Curie

Paris (France), September 1st, 2022 – 8 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North[1]: ONXEO), a […]


Onxeo announces that Nasdaq approved the delisting of its shares from the First North Growth market in Copenhagen

Last day of trading on the First North Growth market on November 8, 2022 Listing on Euronext Growth Paris remains […]


Combined General Meeting of August 17, 2022: Onxeo shareholders approve withdrawal from the Nasdaq First North market in Copenhagen

Company to submit delisting request to Nasdaq   Paris (France), August 17, 2022 – 08:00 pm CEST – Onxeo S.A. […]


Page 1 of 43

No more results